Law Firm Reminds Investors of Filing Deadline in Class Action Lawsuit Against Neumora Therapeutics, Inc.

NMRA Deadline in 1 Day: Kessler Topaz Meltzer Check LLP Reminds Neumora Therapeutics Inc. (NMRA) Investors

VALLEY VILLAGE, PA / ACCESSWIRE / April 27, 2022 / Kessler Topaz Meltzer Check, LLP reminds investors that the deadline to file a lead plaintiff motion in the class action lawsuit on behalf of all persons who purchased or acquired Neumora Therapeutics Inc. ("Neumora Therapeutics" or the "Company") (NASDAQ: NMRA) securities between April 14, 2021 and April 14, 2022, inclusive, is approaching.

A class action lawsuit has been filed on behalf of all persons who purchased or acquired Neumora Therapeutics securities during the Class Period. This action is brought to recover damages caused by Neumora Therapeutics' violations of federal securities laws, including Sections 10(b) and 20 of the Securities Exchange Act of 1934, and Rule 10b-5.

The lawsuit alleges that throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Neumora Therapeutics' lead product candidate, NM304, was not as effective as the company had represented; (2) the Company's clinical trial results were not reliable; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you acquired Neumora Therapeutics securities during the Class Period, you may be able to participate in this case or share in any settlement. For more information or to learn how to participate in this action, please contact Kessler Topaz Meltzer Check, LLP toll-free at (844) 887-7099, or via e-mail at info@kesslermeltzer.com.

Kessler Topaz Meltzer Check, LLP is a boutique securities litigation law firm that specializes in representing the rights of individual investors and institutional clients in securities and shareholder litigation. For more information about Kessler Topaz Meltzer Check, LLP, please visit www.kesslermeltzer.com.